Take a look at the following article from MSN dated August 17th, research by Zach’s; it’s what drew my attention to this stock. I don’t believe the initial Phase III trails were totally successful, so I’ve held off buying. I may throw $500 at it with a stop/loss and see what happens. The nice thing about Imagify is there is no radioactivity, so less overall expense to hospitals.
https://news.moneycentral.msn.com/ticker/article.aspx?Feed=BW&Date=20070813&ID=7316413&Symbol=ACUS
It's been a little less than four months since the RAMP-2 data came out, and Acusphere ACUS shares are down 65% since then. Wall Street clearly thinks the company's drug Imagify has little chance for approval. In the meantime, cash burn is a concern and management is going to have to figure out how to raise money yet again in 2008. As a result, the Street views ACUS like a sinking ship.
With all that said, the opinion of medical and echo-cardiology community couldn't be more different from that of Wall Street. Cardiologists are excited about the data and the clear majority expects the use the drug immediately upon approval. Why is there such a split opinion, and who is right?
It is clear to us that this drug works, and is an extremely useful tool in the diagnosis of coronary artery disease (CAD). Looking at the tapes we quickly forgot about the botched trial endpoints, the dilutive offerings, and the mismanaged expectations of Wall Street. What we saw was powerful - a drug that really does do what it says, regardless of the statistical rigmarole.
Take a look at the following article from MSN dated August 17th, research by Zach’s; it’s what drew my attention to this stock. I don’t believe the initial Phase III trails were totally successful, so I’ve held off buying. I may throw $500 at it with a stop/loss and see what happens. The nice thing about Imagify is there is no radioactivity, so less overall expense to hospitals.
https://news.moneycentral.msn.com/ticker/article.aspx?Feed=BW&Date=20070813&ID=7316413&Symbol=ACUS
It's been a little less than four months since the RAMP-2 data came out, and Acusphere ACUS shares are down 65% since then. Wall Street clearly thinks the company's drug Imagify has little chance for approval. In the meantime, cash burn is a concern and management is going to have to figure out how to raise money yet again in 2008. As a result, the Street views ACUS like a sinking ship.
With all that said, the opinion of medical and echo-cardiology community couldn't be more different from that of Wall Street. Cardiologists are excited about the data and the clear majority expects the use the drug immediately upon approval. Why is there such a split opinion, and who is right?
It is clear to us that this drug works, and is an extremely useful tool in the diagnosis of coronary artery disease (CAD). Looking at the tapes we quickly forgot about the botched trial endpoints, the dilutive offerings, and the mismanaged expectations of Wall Street. What we saw was powerful - a drug that really does do what it says, regardless of the statistical rigmarole.
If you choose to make use of any information on this website including online sports betting services from any websites that may be featured on this website, we strongly recommend that you carefully check your local laws before doing so.It is your sole responsibility to understand your local laws and observe them strictly.Covers does not provide any advice or guidance as to the legality of online sports betting or other online gambling activities within your jurisdiction and you are responsible for complying with laws that are applicable to you in your relevant locality.Covers disclaims all liability associated with your use of this website and use of any information contained on it.As a condition of using this website, you agree to hold the owner of this website harmless from any claims arising from your use of any services on any third party website that may be featured by Covers.